Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Frank M. Balis(National Institutes of Health), Miranda Hughes(National Comprehensive Cancer Network), Daniel S. Rhee(Johns Hopkins University), Mark Ranalli(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Daniel M. Green(St. Jude Children's Research Hospital), Jasreman Dhillon(Moffitt Cancer Center), Kenneth W. Gow, Iain MacEwan(University of California San Diego), Julián A. Martínez-Agosto(University of California, Los Angeles), Michael F. Walsh(Memorial Sloan Kettering Cancer Center), T.Z. Vern-Gross, Elisabeth T. Tracy(University of North Carolina at Chapel Hill), Elizabeth A. Mullen(United States National Library of Medicine), Denise A. Rokitka(Roswell Park Comprehensive Cancer Center), Harold N. Lovvorn(Vanderbilt University Medical Center), Jonathan E. Wickiser(Southwestern Medical Center), Shelly Cook(University of Wisconsin Carbone Cancer Center), Rama Jasty‐Rao(University of Michigan), Erin S. Murphy(Cleveland Clinic), Matthew A. Zapala(Salk Institute for Biological Studies), Ryan A. Berardi(Pancreatic Cancer Action Network), Clarke Anderson(City Of Hope National Medical Center), Susan M. Hiniker(Stanford University), Chi Lin(Susan Thompson Buffett Foundation), Amy L. Walz(Robert H. Lurie Comprehensive Cancer Center of Northwestern University)
Cited by 49
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Germline Mutations in Predisposition Genes in Pediatric Cancer
|New England Journal of Medicine|2015|1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
|Journal of Clinical Oncology|2016|867